NCT06777485招募中不适用
China Liver Cancer Clinical Registry Cohort Database (HEAL)
Anhui Provincial Hospital38 个研究点 分布在 1 个国家目标入组 10,000 人开始时间: 2025年1月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 10,000
- 试验地点
- 38
- 主要终点
- OS
研究概览
简要总结
This study was led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close cooperation with many participating units across the country, to establish a standardized clinical information database of hepatocellular carcinoma cohorts, which will provide a guarantee for conducting high-quality real-world clinical studies and clinical research.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years, no gender limit
- •Patients without surgery are initially diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of imaging and laboratory tests, or patients with surgery are diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of pathologic tests
- •Signed informed consent, good compliance, willingness to accept follow-up and provide blood and postoperative pathology residual samples
排除标准
- •Combination of severe central nervous system disease, respiratory disease, autoimmune disease, chronic renal insufficiency, long-term use of immunosuppressive drugs, combination of severe uncontrolled infections
- •Concurrent active cardiovascular disease, cerebrovascular accident within 6 months, myocardial infarction, unstable angina pectoris, or congestive heart failure of class II or greater according to the New York Heart Association criteria, severe arrhythmia requiring medication
- •Pregnant or breastfeeding women
- •Participation in other therapeutic clinical trials during the course of the patient's illness in which the treatment cannot be specified or information about the treatment cannot be collected
研究组 & 干预措施
Liver Cancer
Observation of clinical routine treatment in patients with Liver cancer
干预措施: Procedure/Surgery treatment (Procedure)
Liver Cancer
Observation of clinical routine treatment in patients with Liver cancer
干预措施: Anti-Tumor Drugs (Drug)
结局指标
主要结局
OS
时间窗: 10 years
Time from enrollment to first recorded occurrence of death from any cause
次要结局
- RFS(10 years)
- Survival time after recurrence(10 years)
研究者
研究点 (38)
Loading locations...
相似试验
招募中
不适用
Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCCHepatocellular CarcinomaNCT05596630Second Affiliated Hospital, School of Medicine, Zhejiang University40
招募中
不适用
A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Liver CancerHepatitisLiver CancerLiver CirrhosisFatty LiverNCT05719480Nanfang Hospital, Southern Medical University2,000
招募中
不适用
Study to compile a register of the Liver Cancer Center Heidelberg (LCCH-Register).C23C22C24Malignant neoplasm of gallbladderMalignant neoplasm of liver and intrahepatic bile ductsMalignant neoplasm of other and unspecified parts of biliary tractDRKS00019901niversitätsklinikum Heidelberg6,000
招募中
不适用
Correlation Study of Lipid Metabolites as Markers of Hepatocellular CarcinomaHepatocellular CarcinomaNCT06623474Nanfang Hospital, Southern Medical University900
已完成
不适用
Hepatocellular Carcinoma Registry for Turkey (3K Trial)Hepatocellular CarcinomaNCT01473121Bayer600